Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - Lee, CK; Chon, HJ; Cheon, J (Lancet Gastroenterol Hepatol, 2023)